Treatment of Coronary Artery Disease: Many Options, but Drug-Eluting Stents Dominate (MMD Report)

Treatment of coronary artery disease has become a hotbed for evaluation of an incredible range of alternatives, but drug-eluting stents (DES) clearly represent the most attractive option, according to a new report from MedMarket Diligence (MMD).

Press Release (PressBurner) May 28, 2009 - Treatment of coronary artery disease has become a sort of living laboratory for the evaluation of an incredible range of alternatives, but drug-eluting stents (DES) represent the most attractive option, from the perspective of patient and clinician alike.

"The use of drug-eluting stents for treatment of coronary artery disease is, in the mind of many, a competitive advantage that no other surgical or even interventional option can challenge," says Patrick Driscoll, President of MedMarket Diligence and publisher of the May 2009 report, "Worldwide Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017."  According to Driscoll, the success of DES is simply evidenced by the number of companies pursuing DES development.  "Follow on manufacturers have been aggressively seeking to gain shares of the multi-billion dollar pie once owned by Johnson & Johnson, but now dominated by J&J, Boston Scientific and Abbott Laboratories," he says.

Put simply, the options for patients fall generally to either a coronary artery bypass graft procedure to simply reroute new graft plumbing around the old, clogged pipes, or revascularizing the clogged arteries via a catheter-based procedure.  However, the variation even across just these two choices is extraordinary now and will continue to be more complex.  Nonetheless, the specific option garnering the highest growth caseload is drug-eluting stents, due to their ability to be implanted minimally invasively via catheter, thereby avoiding the trauma of sternotomy necessary for coronary artery bypass graft (CABG) procedures, and the positive outcomes engendered by the anti-restenosis provided by drug coatings.

Nonetheless, the medtech arena never remains completely static, so shares of caseload will continue to shift as new technologies and therapeutic options (e.g., bioresorbable stents) continue to be developed and tested.

The "Worldwide Market for Drug-Eluting, Bare Metal and Bioabsorbable Stents, 2008-2017," is the subject of the May 2009 report from MedMarket Diligence.  This report details the worldwide market for the use of coronary stents in the treatment of coronary artery disease.  The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.  The report details currently approved coronary stents, providing data on current and forecast impact on the market.  The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction.  The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World.  The report provides competitor market shares by these geographic regions.  The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The report is described in detail at http://mediligence.com/rpt/rpt-c245.htm. It may be purchased online at http://www.mediligence.com/store/page30.html or it may be ordered via fax order form http://mediligence.com/order_forms/c245_order.pdf.

# # #

Release Date: 
Thursday, May 28, 2009 - 2:27am
Additional Tags: 
Reports, coronary, atherosclerosis, drug eluting stent, angioplasty, cypher, taxus
Media Contact
Country: 
United States
State: 
California
Phone: 
949.859.3401
Fax: 
949.837.4558